Drug Delivery and Molecular Sensing

The Drug Delivery and Molecular Sensing Program is based on strengths in cancer research at PCCR that closely match new initiatives from the National Cancer Institute (NCI). In particular, the NCI has proposed new initiatives in imaging, nanotechnology, genomics, proteomics and biomarker discovery. 

Most of the participants in the program are molecular tool designers and developers. Research activities include: 

  • Synthesis and use of molecular probes.
  • Development of drug delivery technologies and devices.
  • Design and construction of nanoparticles for cellular studies and diagnostics.
  • Development of “omics” tools.
  • Development of molecular imaging technologies.
  • Development of tools for probing biomolecular structure and function. 

A number of participants are developing mass spectrometry, nuclear magnetic resonance or flow cytometry for applications in cancer diagnostics. Others are focusing on imaging tools for visualization of events at the cellular level associated with cancer or silicon-based nanowire and microscale cantilevers for sensing biological macromolecules and viruses. 

Participants in the Drug Delivery and Molecular Sensing Program consult with investigators in the Cell Growth and Differentiation, the Drug Design and Discovery, and the Chemical and Structural Biology programs on the selection of molecular targets, synthesis of new molecules and selection of cell and animal model systems. 

Program leaders 

Bumsoo Han, Co-Leader (Mechanical and Biomedical Engineering)

Sophie Lelivre, Co-Leader (Veterinary Medicine)

View our entire membership list.